Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAP1LC3B | Q9GZQ8 | 6/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837246 | 0.80 | MAPT (0.41) | ALDH1A1MAPTGAANPSR1L3MBTL1 | |
| SCHEMBL6837311 | 0.75 | MAP1LC3B (0.47) | ALDH1A1MAPTGAANPSR1L3MBTL1 | |
| SCHEMBL13855924 | 0.75 | POLB (0.61) | ALDH1A1MAPTGAANPSR1L3MBTL1 | |
| SCHEMBL10098421 | 0.75 | POLB (0.61) | ALDH1A1MAPTGAANPSR1L3MBTL1 | |
| SCHEMBL17887331 | 0.74 | MAPT (0.41) | ALDH1A1MAPTGAANPSR1L3MBTL1 | |
| SCHEMBL60469 | 0.73 | ALDH1A1 (0.47) | ALDH1A1MAPTGAANPSR1L3MBTL1 | |
| SCHEMBL18871095 | 0.73 | APP (0.46) | ALDH1A1MAPTGAAL3MBTL1APP | |
| SCHEMBL3142596 | 0.71 | SMN1; SMN2 (0.52) | ALDH1A1MAPTGAANPSR1L3MBTL1 | |
| SCHEMBL581954 | 0.71 | ALDH1A1 (0.46) | ALDH1A1MAPTGAANPSR1L3MBTL1 | |
| SCHEMBL7648836 | 0.71 | ALDH1A1 (0.46) | ALDH1A1MAPTGAANPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192705-A1 | SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-11529321-B2 | Use of aminomethylenecyclohexane-1,3-dione compound | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-12-20 | — | — | US | disclosed |
| EP-3237385-B1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | US HEALTH (US) | 2021-11-24 | — | — | EP | disclosed |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200170966-A1 | USE OF AMINOMETHYLENECYCLOHEXANE-1,3-DIONE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-04 | — | — | US | disclosed |
| US-20190071434-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | THE USA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES (US) | 2019-03-07 | — | — | US | disclosed |
| WO-2016106331-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | THE UNITED STATES OF AMERICA (US) | 2016-06-30 | — | — | WO | disclosed |
| US-8697744-B2 | Substituted 5,6-dihydro-4H-thiazolo[4,5-E]indazoles and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20130210807-A1 | Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors. | MERCK SHARP & DOHME CORP. | 2013-08-15 | — | — | US | disclosed |
| US-20130210807-A1 | Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors. | MERCK SHARP & DOHME CORP. | 2013-08-15 | — | — | US | disclosed |
| EP-2382219-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010079238-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2010-07-15 | — | — | WO | disclosed |
| US-20090234111-A1 | Novel Lactosamine Derivatives | GLYCOM APS (DK) | 2009-09-17 | — | — | US | disclosed |
| US-20090234111-A1 | Novel Lactosamine Derivatives | GLYCOM APS (DK) | 2009-09-17 | — | — | US | disclosed |
| WO-2007104311-A1 | NOVEL LACTOSAMINE DERIVATIVES | GLYCOM APS (DK) | 2007-09-20 | — | — | WO | disclosed |
| US-6765089-B1 | FOR USE IN THE SYNTHESIS OF PEPTIDES, OLIGOSACCHARIDES, GLYCOPEPTIDES AND GLYCOLIPIDS | ALCHEMIA PTY LTD (AU) | 2004-07-20 | — | — | US | disclosed |
| WO-1998005671-A1 | ORGANOSILICON COMPOUNDS AND THEIR USE IN COMBINATORIAL CHEMISTRY | OXFORD ASYMMETRY INTERNATIONAL PLC. (GB) | 1998-02-12 | — | — | WO | disclosed |
| EP-0590558-B1 | Pharmaceutical composition containing 1,5,6,7-tetrahydro-4H-indazol-4-ones,new 1,5,6,7-tetrahydro-4H-indazol-4-ones and process for their manufacture | THOMAE GMBH DR K (DE) | 1995-12-06 | — | — | EP | disclosed |
| US-5468766-A | Analgesics, antipyretics, antiphlogistics | DR. KARL THOMAE GMBH (DE) | 1995-11-21 | — | — | US | disclosed |
| EP-0590558-A1 | Pharmaceutical composition containing 1,5,6,7-tetrahydro-4H-indazol-4-ones,new 1,5,6,7-tetrahydro-4H-indazol-4-ones and process for their manufacture | Dr. Karl Thomae GmbH (DE) | 1994-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210807-A1 | Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors. | GRM3, GRM6, GRM1 | ALDH1A1 3550/4885MAPT 3677/4885GAA 4819/4885 |
| US-20230192705-A1 | SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF | PTPN1, PTPN7, PTPN22 | ALDH1A1 4106/4885MAPT 4450/4885GAA 1010/4885 |
| US-20090234111-A1 | Novel Lactosamine Derivatives | B3GNT2, FUT6, FUT5 | ALDH1A1 1300/4885MAPT 4453/4885GAA 174/4885 |
| US-20200170966-A1 | USE OF AMINOMETHYLENECYCLOHEXANE-1,3-DIONE COMPOUND | ATG7, BECN1, SQSTM1 | ALDH1A1 3815/4885MAPT 584/4885GAA 896/4885 |
| US-11529321-B2 | Use of aminomethylenecyclohexane-1,3-dione compound | ATG7, BECN1, SQSTM1 | ALDH1A1 3815/4885MAPT 584/4885GAA 896/4885 |
| US-20190071434-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | IDH1, IDH3B, IDH3A | ALDH1A1 417/4885MAPT 4568/4885GAA 141/4885 |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | IDH1, IDH3B, IDH3A | ALDH1A1 417/4885MAPT 4568/4885GAA 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.